

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS.

For further information contact:

Vigmed's rights issue fully subscribed

Chairman of the board
Lennart Holm
+46 706 30 85 62 or

CEO
Finn Ketler
+46 42 600 53 11

"The fact that Vigmed's rights issue was oversubscribed demonstrates the strong belief and expectations on the Company and its future development. Through this successful rights issue, Vigmed has guaranteed the required capital to enter the next phase - the commercialisation phase - where Vigmed will continuously and rapidly establish distribution channels in several new markets. It is with great confidence I look forward to a continuing strong development and expansion during 2015", says Lennart Holm, Chairman of the Board, Vigmed Holding AB.

The final result of Vigmed Holding AB's (publ) ("Vigmed") rights issue shows that approximately 6.2 million shares, representing approximately 98.3 percent of the offered shares, were subscribed for by the exercise of subscription rights. In addition, subscription forms corresponding to approximately 1.3 million shares, corresponding to approximately 20.4 percent of the offered shares, have been received. The rights issue is thereby fully subscribed. Through the rights issue, Vigmed will receive proceeds amounting to approximately SEK 56.4 million before transaction costs.

The shares that have not been subscribed for with preferential rights have been allotted in accordance with the principles outlined in the prospectus. Only those who are allotted shares will be notified. Through the rights issue Vigmed's share capital increases by approximately SEK 126,382.86 to approximately SEK 884,680.11. The total number of shares increases by 6,261,904 to 43,833,332 shares.

The final day for trading in paid subscribed shares (BTAs) is expected to be 17 December 2014. The new shares are expected to start trading on NASDAQ First North on 23 December 2014.

ABG Sundal Collier is acting as financial advisor and Mannheimer Swartling Advokatbyrå is acting as legal advisor to Vigmed in connection with the rights issue.

Vigmed discloses the information in this press release pursuant to the Swedish Securities Markets Act. The information was provided for public release on 2 December 2014 at 08:00 CET.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5,400 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information such as company description, a video presentation and risk factors can be found on Vigmed's home page: www.vigmed.com/investor